The response to first‐line therapy with proton pump inhibitors (PPI) defines the new subtypes of eosinophilic GI diseases, namely PPI‐unresponsive and often IgE‐associated EoE versus PPI‐responsive oesophageal eosinophilia.76 Here, IGHE is linked to eosinophilic esophagitis.